Product Code: PHA1211
The Antibody Drug Conjugates market is projected to grow at a CAGR of 15.1% by 2032.
“The Antibody Drug Conjugates Market Report 2022-2032”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Effective and Targeted Medicines are Gaining Traction
Effective and targeted medicines are urgently required in the worldwide health emergency brought on by the (COVID-19) pandemic. Since antibody therapies are relatively simple to develop in comparison to conventional small-molecular medications and are just as precise as vaccines in focusing on the SARS-CoV-2 coronavirus, they have received a lot of attention recently. Seven SARS-CoV-2 antibodies having 3D structures that have been stored in the Protein Data Bank are reviewed (PDB). The possibility of five 3D antibody structures linked to the SARS-CoV spike (S) protein to neutralize SARS-CoV-2 is also assessed. These antibodies' interactions with the S protein receptor-binding domain (RBD) are contrasted with the interactions between complexes including ACE2 and the RBD.
Antibody-Drug Conjugates (ADCs) For Cancer Therapy for Drawing Attention from All over the World
Significant traction has been observed for this market owing to the abundance of newly developed antibody-drug conjugates (ADCs) for cancer therapy, drawing attention from all over the world. Even though finding an appropriate mix of an antibody, a linker, and a payload for an ADC can be quite difficult, as of September 2021, 11 ADCs had received FDA clearance, with eight of those being approved in 2017. In 2020, many mergers and partnerships were recorded in the ADC sector despite the COVID-19 pandemic, demonstrating that Big Pharma is highly interested in this therapeutic approach.
What Questions Should You Ask before Buying a Market Research Report?
- How is the antibody drug conjugates market evolving?
- What is driving and restraining the antibody drug conjugates market?
- How will each antibody drug conjugates submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each antibody drug conjugates submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading antibody drug conjugates markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the antibody drug conjugates projects for these leading companies?
- How will the industry evolve during the period between 2020 and 2032? What are the implications of antibody drug conjugates projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the antibody drug conjugates market?
- Where is the antibody drug conjugates market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the antibody drug conjugates market today, and over the next 10 years:
- Our 434- page report provides 184 tables and 242 charts /graphs exclusively to you
- The report highlights key lucrative areas in the industry so you can target them - NOW
- It contains in-depth analysis of global, regional and national sales and growth
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the antibody drug conjugates market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares
- You will find original analyses, with business outlooks and developments
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising antibody drug conjugates prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Market Segment by Payload Type
- MMAE
- DM4
- Camptothecin
- DM1
- MMAF
- Other Payload Type
Market Segment by Technology
- Cleavable Linkers
- Non-Cleavable Linkers
- Other Technology
Market Segment by Linker Type
- VC
- Sulfo-SPDB
- SMCC
- Other Linker Type
- VA
- Hydrazone
Market Segment by Target Antigen
- CD30
- HER2
- CD22
- CD33
- Other Target Antigen
Market Segment by Application
- Blood Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumor
- Other Application
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:
North America
Europe
- Germany
- Russia
- United Kingdom
- France
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
South America
- Brazil
- Mexico
- Rest of South America
Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
The report also includes profiles and for some of the leading companies in the Antibody Drug Conjugates Market, 2022 to 2032, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth:
- AbbVie Inc. Company
- Astellas Pharma Inc
- Bayer AG
- Celldex Therapeutics, Inc
- F. Hoffmann-La Roche Ltd
- Genentech, Inc
- Gilead Sciences, Inc
- ImmunoGen, Inc
|
- Lantheus Holdings, Inc
- Lonza Group AG
- Merck KGaA
- Mersana Therapeutics Inc
- Pfizer Inc
- Seagen Inc
- Takeda Pharmaceutical Company Limited
|
Overall world revenue for Antibody Drug Conjugates Market, 2022 to 2032 in terms of value the market will surpass US$4,182 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Antibody Drug Conjugates Market, 2022 to 2032 report help you?
In summary, our 430+ page report provides you with the following knowledge:
- Revenue forecasts to 2032 for Antibody Drug Conjugates Market, 2022 to 2032 Market, with forecasts by payload type, technology, linker type, target antigen, application, and company size, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Antibody Drug Conjugates Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, Russia, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Antibody Drug Conjugates Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
Table of Contents
1. Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Antibody Drug Conjugates Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
2 Executive Summary
- 2.1 Geographical Snapshot: Global Antibody Drug Conjugates Market
- 2.2 Technology Segment: Market Attractiveness Index
- 2.3 Payload Type Segment: Market Attractiveness Index
- 2.4 Target Antigen Segment: Market Attractiveness Index
- 2.5 Linker Type Segment: Market Attractiveness Index
- 2.6 Application Segment: Market Attractiveness Index
3 Market Overview
- 3.1 Key Findings
- 3.2 ADCs Market
- 3.2.1 FDA Approved Antibody Drug Conjugates
- 3.3 Supply Chain
- 3.4 Value Chain
- 3.5 Cold chain
- 3.6 Recent Trends/ Developments
- 3.7 Market Dynamics
- 3.7.1 Market Driving Factors
- 3.7.2 Market Restraining Factors
- 3.7.3 Market Opportunities
- 3.8 COVID-19 Impact Analysis
- 3.9 Porter's Five Forces Analysis
- 3.9.1 Bargaining Power of Suppliers (High)
- 3.9.2 Bargaining Power of Buyers (Moderate)
- 3.9.3 Competitive Rivalry in the Market (High)
- 3.9.4 Threat from Substitutes (Low)
- 3.9.5 Threat of New Entrants (Low)
- 3.10 PESTLE Analysis
- 3.10.1 Political
- 3.10.2 Economical
- 3.10.3 Social
- 3.10.4 Technological
- 3.10.5 Legal
- 3.10.6 Environmental
4 Global Antibody Drug Conjugates Market Analysis
- 4.1 Key Findings
- 4.2 Global Market Outlook
- 4.3 Region Segment Growth Prospects
- 4.4 Global Antibody Drug Conjugates Market Share by Region, 2022 & 2032
- 4.5 Global Antibody Drug Conjugates Market Share Forecast
- 4.5.1 Pre-COVID-19 Market Scenario
- 4.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
- 4.6 Global Pharma Contract Sales Market by Region Size Estimation and Forecast
- 4.6.1 Pre-COVID-19 Market Scenario
- 4.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
5 Global Antibody Drug Conjugates Market Analysis by Technology
- 5.1 Key Findings
- 5.2 Global Technology Market Outlook
- 5.3 Global Antibody Drug Conjugates by Technology Market Attractiveness Index
- 5.4 Regional Market Size Estimation and Forecast
- 5.5 Cleavable Linkers
- 5.5.1 Global Cleavable Linkers Market Forecast
- 5.5.2 Global Cleavable Linkers Market Forecast by Region
- 5.6 Non-Cleavable Linkers
- 5.6.1 Global Non-Cleavable Linkers Market Forecast
- 5.6.2 Global Non-Cleavable Linkers Market Forecast by Region
- 5.7 Other Technology
- 5.7.1 Global Other Technology Market Forecast
- 5.7.2 Global Other Technology Market Forecast by Region
6 Global Antibody Drug Conjugates Market Analysis by Payload Type
- 6.1 Key Findings
- 6.2 Global Payload Type Market Outlook
- 6.3 Global Antibody Drug Conjugates by Payload Type Market Attractiveness Index
- 6.4 Global Antibody Drug Conjugates Market by Payload Type
- 6.5 MMAE
- 6.5.1 Global MMAE Market Forecast
- 6.5.2 Global MMAE Market Forecast by Region
- 6.6 DM4
- 6.6.1 Global DM4 Market Forecast
- 6.6.2 Global DM4 Market Forecast by Region
- 6.7 Camptothecin
- 6.7.1 Global Camptothecin Market Forecast
- 6.7.2 Global Camptothecin Market Forecast by Region
- 6.8 DM1
- 6.8.1 Global DM1 Market
- 6.8.2 Global DM1 Market Forecast by Region
- 6.9 MMAF
- 6.9.1 Global MMAF Market Forecast
- 6.9.2 Global MMAF Market Forecast by Region
- 6.10 Other Payload Type
- 6.10.1 Global Other Payload Type Market Forecast
- 6.10.2 Global Other Payload Type Market Forecast by Region
7 Global Antibody Drug Conjugates Market Analysis by Target Antigen
- 7.1 Key Findings
- 7.2 Global Target Antigen Market Outlook
- 7.3 Global Antibody Drug Conjugates by Target Antigen Market Attractiveness Index
- 7.4 Global Antibody Drug Conjugates Market by Target Antigen
- 7.5 CD30
- 7.5.1 Global CD30 Market Forecast
- 7.5.2 Global CD30 Market Forecast by Region
- 7.6 HER2
- 7.6.1 Global HER2 Market Forecast
- 7.6.2 Global HER2 Market Forecast by Region
- 7.7 CD22
- 7.7.1 Global CD22 Market Forecast
- 7.7.2 Global CD22 Market Forecast by Region
- 7.8 CD33
- 7.8.1 Global CD33 Market Forecast
- 7.8.2 Global CD33 Market Forecast by Region
- 7.9 Other Target Antigen
- 7.9.1 Global Other Target Antigen Market Forecast
- 7.9.2 Global Other Target Antigen Market Forecast by Region
8 Global Antibody Drug Conjugates Market Analysis by Linker Type
- 8.1 Key Findings
- 8.2 Global Linker Type Market Outlook
- 8.3 Global Antibody Drug Conjugates by Linker Type Market Attractiveness Index
- 8.4 Global Antibody Drug Conjugates Market by Linker Type
- 8.5 VC
- 8.5.1 Global VC Market Forecast
- 8.5.2 Global VC Market by Region
- 8.6 Sulfo-SPDB
- 8.6.1 Global Sulfo-SPDB Market Forecast
- 8.6.2 Global Sulfo-SPDB Market by Region
- 8.7 SMCC Market
- 8.7.1 Global SMCC Market Forecast
- 8.7.2 Global SMCC Market by Region
- 8.8 VA
- 8.8.1 Global VA Market Forecast
- 8.8.2 Global VA Market by Region
- 8.9 Hydrazone
- 8.9.1 Global Hydrazone Market Forecast
- 8.9.2 Global Hydrazone Market by Region
- 8.10 Other Linker Type
- 8.10.1 Global Other Linker Type Market Forecast
- 8.10.2 Global Other Linker Type Market by Region
9 Global Antibody Drug Conjugates Market Analysis by Application
- 9.1 Key Findings
- 9.2 Global Application Market Outlook
- 9.3 Global Antibody Drug Conjugates by Application Market Attractiveness Index
- 9.4 Global Antibody Drug Conjugates Market by Application
- 9.5 Blood Cancer
- 9.5.1 Global Blood Cancer Market Forecast
- 9.5.2 Global Blood Cancer Market by Region
- 9.6 Breast Cancer
- 9.6.1 Global Breast Cancer Market Forecast
- 9.6.2 Global Breast Cancer Market by Region
- 9.7 Ovarian Cancer
- 9.7.1 Global Ovarian Cancer Market Forecast
- 9.7.2 Global Ovarian Cancer Market by Region
- 9.8 Lung Cancer
- 9.8.1 Global Lung Cancer Market Forecast
- 9.8.2 Global Lung Cancer Market by Region
- 9.9 Brain Tumor
- 9.9.1 Global Brain Tumor Market Forecast
- 9.9.2 Global Brain Tumor Market by Region
- 9.10 Other Application
- 9.10.1 Global Other Application Market Forecast
- 9.10.2 Global Other Application Market by Region
10 North America Antibody Drug Conjugates Market Analysis
- 10.1 Key Findings
- 10.2 The Global Antibody Drug Market is predominated by North America
- 10.3 North America Antibody Drug Conjugates Market Attractiveness Index
- 10.4 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Value
- 10.5 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
- 10.6 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
- 10.7 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
- 10.8 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
- 10.9 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
- 10.10 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Application
- 10.11 U.S.
- 10.11.1 U.S. Antibody Drug Conjugates Market by Value
- 10.12 Canada
- 10.12.1 Canada Antibody Drug Conjugates Market by Value
11 Europe Antibody Drug Conjugates Market Analysis
- 11.1 Key Findings
- 11.2 Europe Antibody Drug Conjugates Market Attractiveness Index
- 11.3 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Value
- 11.4 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Country
- 11.5 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
- 11.6 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
- 11.7 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
- 11.8 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
- 11.9 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Application
- 11.10 Germany
- 11.10.1 Germany Antibody Drug Conjugates Market by Value
- 11.11 U.K.
- 11.11.1 U.K. Antibody Drug Conjugates Market by Value
- 11.12 France
- 11.12.1 France Antibody Drug Conjugates Market by Value
- 11.13 Italy
- 11.13.1 Italy Antibody Drug Conjugates Market by Value
- 11.14 Russia
- 11.14.1 Russia Antibody Drug Conjugates Market by Value
- 11.15 Rest of Europe
- 11.15.1 Rest of Europe Antibody Drug Conjugates Market by Value
12 Asia-Pacific Antibody Drug Conjugates Market Analysis
- 12.1 Key Findings
- 12.2 Asia-Pacific Antibody Drug Conjugates Market Attractiveness Index
- 12.3 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Value
- 12.4 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Country
- 12.5 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
- 12.6 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
- 12.7 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
- 12.8 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
- 12.9 Asia-Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Application
- 12.10 China
- 12.10.1 China Antibody Drug Conjugates Market by Value
- 12.11 India
- 12.11.1 India Antibody Drug Conjugates Market by Value
- 12.12 Japan
- 12.12.1 Japan Antibody Drug Conjugates Market by Value
- 12.13 South Korea
- 12.13.1 South Korea Antibody Drug Conjugates Market by Value
- 12.14 Australia
- 12.14.1 Australia Antibody Drug Conjugates Market by Value
- 12.15 Rest of Asia-Pacific
- 12.15.1 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value
13 Middle East & Africa Antibody Drug Conjugates Market Analysis
- 13.1 Key Findings
- 13.2 Middle East & Africa Antibody Drug Conjugates Market Attractiveness Index
- 13.3 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Value
- 13.4 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Country
- 13.5 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
- 13.6 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
- 13.7 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
- 13.8 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
- 13.9 Middle East & Africa Antibody Drug Conjugates Market Size Estimation and Forecast by Application
- 13.10 South Africa
- 13.10.1 South Africa Antibody Drug Conjugates Market by Value
- 13.11 Saudi Arabia
- 13.11.1 Saudi Arabia Antibody Drug Conjugates Market by Value
- 13.12 U.A.E.
- 13.12.1 U. A.E. Antibody Drug Conjugates Market by Value
- 13.13 Rest of Middle East & Africa
- 13.13.1 Rest of Middle East & Africa Antibody Drug Conjugates Market by Value
14 South America Antibody Drug Conjugates Market Analysis
- 14.1 Key Findings
- 14.2 South America Antibody Drug Conjugates Market Attractiveness Index
- 14.3 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Value
- 14.4 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
- 14.5 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
- 14.6 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
- 14.7 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
- 14.8 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
- 14.9 South America Antibody Drug Conjugates Market Size Estimation and Forecast by Application
- 14.10 Brazil
- 14.10.1 Brazil Antibody Drug Conjugates Market by Value
- 14.11 Mexico
- 14.11.1 Mexico Antibody Drug Conjugates Market by Value
- 14.12 Rest of South America
- 14.12.1 Rest of South America Antibody Drug Conjugates Market by Value
15 Competitive Landscape
- 15.1 Company Share Analysis
- 15.2 Key Business Strategy Analysis- Acquisition
- 15.3 Key Business Strategy Analysis- Agreement
- 15.4 Key Business Strategy Analysis- Collaboration
- 15.5 Key Business Strategy Analysis- Development
- 15.6 Key Business Strategy Analysis- Expansion
- 15.7 Key Business Strategy Analysis- Investment
- 15.8 Key Business Strategy Analysis- Merger
- 15.9 Key Business Strategy Analysis- New Product Launch
- 15.10 Key Business Strategy Analysis- Partnership
16 Company Profiles
- 16.1 Abbvie Inc. Company
- 16.1.1 Company Snapshot
- 16.1.2 Company Overview
- 16.1.3 Financial Analysis
- 16.1.4 Product Benchmarking
- 16.1.5 Strategic Outlook
- 16.2 Astellas Pharma Inc.
- 16.2.1 Company Snapshot
- 16.2.2 Company Overview
- 16.2.3 Financial Analysis
- 16.2.4 Product Benchmarking
- 16.2.5 Strategic Outlook
- 16.3 Bayer AG
- 16.3.1 Company Snapshot
- 16.3.2 Company Overview
- 16.3.3 Financial Analysis
- 16.3.4 Product Benchmarking
- 16.3.5 Strategic Outlook
- 16.4 Celldex Therapeutics, Inc.
- 16.4.1 Company Snapshot
- 16.4.2 Company Overview
- 16.4.3 Financial Analysis
- 16.4.4 Product Benchmarking
- 16.4.5 Strategic Outlook
- 16.5 Genentech, Inc.
- 16.5.1 Company Snapshot
- 16.5.2 Company Overview
- 16.5.3 Product Benchmarking
- 16.5.4 Strategic Outlook
- 16.6 ImmunoGen, Inc.
- 16.6.1 Company Snapshot
- 16.6.2 Company Overview
- 16.6.3 Financial Analysis
- 16.6.4 Product Benchmarking
- 16.6.5 Strategic Outlook
- 16.7 Gilead Sciences, Inc.
- 16.7.1 Company Snapshot
- 16.7.2 Company Overview
- 16.7.3 Financial Analysis
- 16.7.4 Product Benchmarking
- 16.7.5 Strategic Outlook
- 16.8 Lonza Group AG
- 16.8.1 Company Snapshot
- 16.8.2 Company Overview
- 16.8.3 Financial Analysis
- 16.8.4 Product Benchmarking
- 16.8.5 Strategic Outlook
- 16.9 Mersana Therapeutics Inc.
- 16.9.1 Company Snapshot
- 16.9.2 Company Overview
- 16.9.3 Financial Analysis
- 16.9.4 Product Benchmarking
- 16.9.5 Strategic Outlook
- 16.10 Takeda Pharmaceutical Company Limited
- 16.10.1 Company Snapshot
- 16.10.2 Company Overview
- 16.10.3 Financial Analysis
- 16.10.4 Product Benchmarking
- 16.10.5 Strategic Outlook
- 16.11 Pfizer Inc.
- 16.11.1 Company Snapshot
- 16.11.2 Company Overview
- 16.11.3 Financial Analysis
- 16.11.4 Product Benchmarking
- 16.11.5 Strategic Outlook
- 16.12 F. Hoffmann-La Roche Ltd
- 16.12.1 Company Snapshot
- 16.12.2 Company Overview
- 16.12.3 Financial Analysis
- 16.12.4 Product Benchmarking
- 16.12.5 Strategic Outlook
- 16.13 Lantheus Holdings, Inc.
- 16.13.1 Company Snapshot
- 16.13.2 Company Overview
- 16.13.3 Financial Analysis
- 16.13.4 Product Benchmarking
- 16.13.5 Strategic Outlook
- 16.14 Seagen Inc.
- 16.14.1 Company Snapshot
- 16.14.2 Company Overview
- 16.14.3 Financial Analysis
- 16.14.4 Product Benchmarking
- 16.14.5 Strategic Outlook
- 16.15 Merck KGaA
- 16.15.1 Company Snapshot
- 16.15.2 Company Overview
- 16.15.3 Financial Analysis
- 16.15.4 Product Benchmarking
- 16.15.5 Strategic Outlook
17 Conclusion and Recommendations
- 17.1 Concluding Remarks from
- 17.2 Recommendations for Market Players